1. Home
  2. NVCR vs FRME Comparison

NVCR vs FRME Comparison

Compare NVCR & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • FRME
  • Stock Information
  • Founded
  • NVCR 2000
  • FRME 1893
  • Country
  • NVCR Switzerland
  • FRME United States
  • Employees
  • NVCR N/A
  • FRME N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • FRME Major Banks
  • Sector
  • NVCR Health Care
  • FRME Finance
  • Exchange
  • NVCR Nasdaq
  • FRME Nasdaq
  • Market Cap
  • NVCR 1.9B
  • FRME 2.1B
  • IPO Year
  • NVCR 2015
  • FRME N/A
  • Fundamental
  • Price
  • NVCR $17.60
  • FRME $41.26
  • Analyst Decision
  • NVCR Buy
  • FRME Buy
  • Analyst Count
  • NVCR 7
  • FRME 4
  • Target Price
  • NVCR $32.43
  • FRME $44.75
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • FRME 363.9K
  • Earning Date
  • NVCR 07-24-2025
  • FRME 07-23-2025
  • Dividend Yield
  • NVCR N/A
  • FRME 3.46%
  • EPS Growth
  • NVCR N/A
  • FRME 2.61
  • EPS
  • NVCR N/A
  • FRME 3.55
  • Revenue
  • NVCR $621,711,000.00
  • FRME $615,411,000.00
  • Revenue This Year
  • NVCR $5.56
  • FRME $15.14
  • Revenue Next Year
  • NVCR $9.19
  • FRME $5.03
  • P/E Ratio
  • NVCR N/A
  • FRME $11.71
  • Revenue Growth
  • NVCR 18.27
  • FRME N/A
  • 52 Week Low
  • NVCR $14.17
  • FRME $32.90
  • 52 Week High
  • NVCR $34.13
  • FRME $46.13
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • FRME 68.20
  • Support Level
  • NVCR $16.81
  • FRME $39.21
  • Resistance Level
  • NVCR $18.59
  • FRME $41.77
  • Average True Range (ATR)
  • NVCR 0.74
  • FRME 1.46
  • MACD
  • NVCR 0.08
  • FRME 0.38
  • Stochastic Oscillator
  • NVCR 56.18
  • FRME 92.14

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About FRME First Merchants Corporation

First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.

Share on Social Networks: